Myopenia and body fat distribution in hospitalized ulcerative colitis patients: correlations with clinical characteristics and response to vedolizumab

BackgroundUlcerative colitis (UC) patients often suffer from impaired nutritional conditions. However, there are few studies focused on muscle loss in UC patients as well as its impact on therapeutic response. This study aimed to investigate the prevalence of myopenia in hospitalized patients with a...

Full description

Bibliographic Details
Published in:	Frontiers in Nutrition
Main Authors:	Wei Wei, Pengguang Yan, Yan Zhang, Qiong Wang, Junren Kang, Pengju Liu, Jin Fu, Jingnan Li, Kang Yu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Subjects:	myopenia ulcerative colitis adipose tissue visceral obesity vedolizumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fnut.2024.1411695/full

Similar Items

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
by: Dart RJ, et al.
Published: (2017-03-01)

Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study
by: Kei Nomura, et al.
Published: (2024-09-01)

A real-world study of vedolizumab versus infliximab in patients with moderate to severe ulcerative colitis
by: MENG Ruiping, et al.
Published: (2024-06-01)

Leishmania donovani infection mimicking ulcerative colitis in an immuno-competent patient
by: Jonas Buttenschoen, et al.
Published: (2024-10-01)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01)

Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study
by: Zhang C, et al.
Published: (2025-06-01)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
by: Keiichi Haga, et al.
Published: (2022-10-01)

Vedolizumab–steroid combination therapy improves long-term prognosis in patients with ulcerative colitis
by: Yosuke Yamada, et al.
Published: (2025-04-01)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
by: Holger Schäffler, et al.
Published: (2017-12-01)

Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China
by: Hao Zhang, et al.
Published: (2025-07-01)

The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab
by: Jing Yan, et al.
Published: (2025-03-01)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
by: Yusuke Oki, et al.
Published: (2023-05-01)

Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: A systematic review and meta-analysis
by: Maha Alghamdi, et al.
Published: (2024-11-01)

The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group
by: Nahla Azzam, et al.
Published: (2025-01-01)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
by: Kaituo Huang, et al.
Published: (2023-05-01)

Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report
by: Hironobu Takedomi, et al.
Published: (2025-01-01)

IgA vasculitis preceded by pulmonary hemorrhage in a patient with ulcerative colitis during treatment with vedolizumab
by: Natsumi Ikumi, et al.
Published: (2024-08-01)

Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis on hemodialysis for end-stage renal failure: a case report
by: Zezheng Wang, et al.
Published: (2025-09-01)

Anti-integrin treatment as an effective alternative for a patient with ulcerative colitis
by: Ewa Biegańska, et al.
Published: (2022-12-01)

Predictive Value of Albumin to Fibrinogen Ratio and CALLY Index for Diagnosis of Ulcerative Colitis and Mucosal Healing After Vedolizumab Treatment
by: Su K, et al.
Published: (2025-01-01)

Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects
by: Yibing Hu, et al.
Published: (2024-12-01)

Colonic Lung Cancer Metastasis in Vedolizumab-Treated Immune Checkpoint Inhibitor Colitis
by: Sean S. Davis, et al.
Published: (2020-07-01)

Treatment of Ulcerative Colitis: Impact on Platelet Aggregation
by: Sasa Peric, et al.
Published: (2023-09-01)

Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan
by: Masashi Omori, et al.
Published: (2024-05-01)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
by: Hamzah Abu-Sbeih, et al.
Published: (2018-12-01)

Aggressive Colorectal Cancer in an Inflammatory Bowel Disease Patient following Treatment with Vedolizumab: A Case Report
by: Catarina Nascimento, et al.
Published: (2021-07-01)

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
by: Ulf Helwig, et al.
Published: (2020-07-01)

Comparative efficacy and safety of vedolizumab and antitumor necrosis factor alfa in patients with inflammatory bowel diseases: A meta‑analysis
by: Li Yafang, et al.
Published: (2025-03-01)

THE FEATURES OF PREOPERATIVE MYOPENIA, MYOSTEATOSIS, AND PHYSICAL FUNCTION IN JAPANESE PATIENTS WITH GASTROINTESTINAL CANCER: A CROSS-SECTIONAL STUDY
by: Noriatsu Tatematsu, et al.
Published: (2023-10-01)

Myopenia is associated with joint damage in rheumatoid arthritis: a cross‐sectional study
by: Jian‐Zi Lin, et al.
Published: (2019-04-01)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
by: Merve Sivridaş, et al.
Published: (2023-03-01)

Identification of key genes and biological processes contributing to colitis associated dysplasia in ulcerative colitis
by: Di Zhang, et al.
Published: (2021-04-01)

Colon and Rectal Surgery for Inflammatory Bowel Disease Patients on Vedolizumab: Preliminary Surgical Outcomes
by: Sarah B. Stringfield, et al.
Published: (2018-01-01)

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
by: Špela Pintar, et al.
Published: (2024-02-01)

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
by: Hye Kyung Hyun, et al.
Published: (2022-03-01)

A product review of vedolizumab in inflammatory bowel disease
by: Robert Battat, et al.
Published: (2019-10-01)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
by: Ayaka Kaneoka, et al.
Published: (2022-02-01)

Circulating miR‐203 derived from metastatic tissues promotes myopenia in colorectal cancer patients
by: Yoshinaga Okugawa, et al.
Published: (2019-06-01)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
by: Abdulaziz Saad Alshahrani, et al.
Published: (2023-09-01)

Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications
by: Diego Casas-Deza, et al.
Published: (2025-08-01)